
The results of the GENEr8-1 and HOPE-B trials in the treatment of hemophilia mark a significant advancement in the field. These trials demonstrate a remarkable variability in patient response. While mean and median levels of factors VIII and IX are useful for comparing studies and tracking patient groups over time, individual hemophilia patients considering gene therapy are more concerned about their personal potential response rather than the overall average and middle values.
Like
Save
Share